Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | EVP and President, Hematology | December 31, 2020 | January 06, 2021 |
| Cullinan Therapeutics, Inc.CGEM · Entity 4766 | Director · President and CEO | February 24, 2026 | February 25, 2026 |
| Disc Medicine, Inc.IRON · Entity 2273 | Director | June 18, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date December 31, 2020 · Filed January 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.10 par valueSEC Table I · non-derivative | Direct | 38,889 |
Ending reported balance
After 2020-12-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-12-31 · Exercise / conversion · Acquired 14,946 · Balance 46,549 F1: In connection with the merger, all outstanding Celgene Corporation (Celgene) Performance Share Unit awards were assumed by BMS and converted into a restricted unit award. The restricted stock unit reported on this Form 4 vests in full on December 31, 2020, which is the end of the original performance period associated with the original Performance Share Unit award. Row 2 · 2020-12-31 · Tax withholding · Disposed 7,660 · Balance 38,889 F2: Shares withheld for payment of taxes upon vesting of awards. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2020-12-31 | Direct | 0 |
Reported balance
After 2020-12-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-12-31 · Exercise / conversion · Disposed 14,946 · Balance 0 F4: Each restricted stock unit converts into one share of common stock upon vesting. F1: In connection with the merger, all outstanding Celgene Corporation (Celgene) Performance Share Unit awards were assumed by BMS and converted into a restricted unit award. The restricted stock unit reported on this Form 4 vests in full on December 31, 2020, which is the end of the original performance period associated with the original Performance Share Unit award. |
| Common Stock, $0.10 par valueSEC Table I · non-derivative | Indirect401(k) | 1,966 |
Reported balance
Holding disclosure · report date 2020-12-31 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,966 F3: Based on recent 401(k) plan statement. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the merger, all outstanding Celgene Corporation (Celgene) Performance Share Unit awards were assumed by BMS and converted into a restricted unit award. The restricted stock unit reported on this Form 4 vests in full on December 31, 2020, which is the end of the original performance period associated with the original Performance Share Unit award.
F2: Shares withheld for payment of taxes upon vesting of awards.
F3: Based on recent 401(k) plan statement.
F4: Each restricted stock unit converts into one share of common stock upon vesting.
Cullinan Therapeutics, Inc.
Report date February 24, 2026 · Filed February 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 390,803 |
Reported balance
After 2026-02-24 transaction · row 1
1 source rowRow 1 · 2026-02-24 · Sale · Disposed 13,515 · Balance 390,803 F1: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.
Disc Medicine, Inc.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.79 · Expires 2036-06-17 | Direct | 5,176 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 5,176 · Balance 5,176 F1: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CELGENE CORP /DE/
Report date November 20, 2019 · Filed November 22, 2019
Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $113.18 · Expires 2027-01-30 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-11-20 · Disposition to issuer · Disposed 6,563 · Balance 0 F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $124.06 · Expires 2027-05-01 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-11-20 · Disposition to issuer · Disposed 3,125 · Balance 0 F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $135.41 · Expires 2027-07-31 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-11-20 · Disposition to issuer · Disposed 3,125 · Balance 0 F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.97 · Expires 2027-10-30 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-11-20 · Disposition to issuer · Disposed 5,000 · Balance 0 F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $103.26 · Expires 2028-01-29 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-11-20 · Disposition to issuer · Disposed 5,000 · Balance 0 F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $83.13 · Expires 2028-05-08 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-11-20 · Disposition to issuer · Disposed 10,548 · Balance 0 F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.91 · Expires 2028-07-30 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-11-20 · Disposition to issuer · Disposed 10,548 · Balance 0 F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.43 · Expires 2028-10-29 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-11-20 · Disposition to issuer · Disposed 10,549 · Balance 0 F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1: This option was fully exercisable. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-11-20 · Disposition to issuer · Disposed 1,563 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F4: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-11-20 · Disposition to issuer · Disposed 2,500 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F4: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-11-20 · Disposition to issuer · Disposed 5,357 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F4: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2019-11-20 · Disposition to issuer · Disposed 3,348 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F4: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2019-11-20 · Disposition to issuer · Disposed 27,749 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F4: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was fully exercisable.
F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
F3: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock.
F4: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $109.90 | $0.00 |
DisclosureSEC source: 0001415889-19-001380 · form4-11222019_071126.xml · derivative · entry 19 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2025-05-04 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 3,750 | $0.00 Strike: $118.57 | $0.00 |
DisclosureSEC source: 0001415889-19-001380 · form4-11222019_071126.xml · derivative · entry 18 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires 2025-02-02 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $117.18 | $0.00 |
DisclosureSEC source: 0001415889-19-001380 · form4-11222019_071126.xml · derivative · entry 17 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2024-12-19 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 3,750 | $0.00 Strike: $103.10 | $0.00 |
DisclosureSEC source: 0001415889-19-001380 · form4-11222019_071126.xml · derivative · entry 16 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 3,750 shares Expires 2024-10-27 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $87.64 | $0.00 |
DisclosureSEC source: 0001415889-19-001380 · form4-11222019_071126.xml · derivative · entry 15 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2024-07-28 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 3,750 | $0.00 Strike: $74.30 | $0.00 |
DisclosureSEC source: 0001415889-19-001380 · form4-11222019_071126.xml · derivative · entry 14 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires 2024-02-03 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $81.56 | $0.00 |
DisclosureSEC source: 0001415889-19-001380 · form4-11222019_071126.xml · derivative · entry 13 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2023-12-02 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 3,750 | $0.00 Strike: $78.12 | $0.00 |
DisclosureSEC source: 0001415889-19-001380 · form4-11222019_071126.xml · derivative · entry 12 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires 2023-10-28 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 3,750 | $0.00 Strike: $71.33 | $0.00 |
DisclosureSEC source: 0001415889-19-001380 · form4-11222019_071126.xml · derivative · entry 11 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires 2023-07-29 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 3,750 | $0.00 Strike: $59.24 | $0.00 |
DisclosureSEC source: 0001415889-19-001380 · form4-11222019_071126.xml · derivative · entry 10 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires 2023-04-29 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 5,626 | $0.00 Strike: $49.48 | $0.00 |
DisclosureSEC source: 0001415889-19-001380 · form4-11222019_071126.xml · derivative · entry 9 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,626 shares Expires 2023-01-28 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $40.22 | $0.00 |
DisclosureSEC source: 0001415889-19-001380 · form4-11222019_071126.xml · derivative · entry 8 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,000 shares Expires 2022-12-17 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 5,626 | $0.00 Strike: $36.68 | $0.00 |
DisclosureSEC source: 0001415889-19-001380 · form4-11222019_071126.xml · derivative · entry 7 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,626 shares Expires 2022-10-31 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 5,624 | $0.00 Strike: $36.47 | $0.00 |
DisclosureSEC source: 0001415889-19-001380 · form4-11222019_071126.xml · derivative · entry 6 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,624 shares Expires 2022-04-30 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 1,750 | $0.00 Strike: $36.36 | $0.00 |
DisclosureSEC source: 0001415889-19-001380 · form4-11222019_071126.xml · derivative · entry 5 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,750 shares Expires 2022-01-30 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerCommon Stock | 1,966 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001380 · form4-11222019_071126.xml · nonDerivative · entry 4 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Indirect · 401(k) Plan Disclosed balance after: 0 F2 · price: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerCommon Stock | 40,694 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001380 · form4-11222019_071126.xml · nonDerivative · entry 3 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantCommon Stock | 17,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001380 · form4-11222019_071126.xml · nonDerivative · entry 2 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,694 F1 · price: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantCommon Stock | 8,035 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001380 · form4-11222019_071126.xml · nonDerivative · entry 1 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,854 F1 · price: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerRestricted Stock Unit · Derivative | 27,749 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001381 · form4-11222019_071130.xml · derivative · entry 13 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,749 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F4 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F4 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F4 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerRestricted Stock Unit · Derivative | 3,348 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001381 · form4-11222019_071130.xml · derivative · entry 12 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,348 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F4 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F4 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F4 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerRestricted Stock Unit · Derivative | 5,357 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001381 · form4-11222019_071130.xml · derivative · entry 11 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,357 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F4 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F4 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F4 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerRestricted Stock Unit · Derivative | 2,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001381 · form4-11222019_071130.xml · derivative · entry 10 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F4 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F4 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F4 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerRestricted Stock Unit · Derivative | 1,563 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001381 · form4-11222019_071130.xml · derivative · entry 9 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,563 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F4 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F4 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F4 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 10,549 | $0.00 Strike: $71.43 | $0.00 |
DisclosureSEC source: 0001415889-19-001381 · form4-11222019_071130.xml · derivative · entry 8 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,549 shares Expires 2028-10-29 F2 · price: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1 · derivative.exercise_date: This option was fully exercisable. F2 · derivative.exercise_date: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 10,548 | $0.00 Strike: $88.91 | $0.00 |
DisclosureSEC source: 0001415889-19-001381 · form4-11222019_071130.xml · derivative · entry 7 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,548 shares Expires 2028-07-30 F2 · price: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1 · derivative.exercise_date: This option was fully exercisable. F2 · derivative.exercise_date: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 10,548 | $0.00 Strike: $83.13 | $0.00 |
DisclosureSEC source: 0001415889-19-001381 · form4-11222019_071130.xml · derivative · entry 6 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,548 shares Expires 2028-05-08 F2 · price: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1 · derivative.exercise_date: This option was fully exercisable. F2 · derivative.exercise_date: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001415889-19-001381 · form4-11222019_071130.xml · derivative · entry 5 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2028-01-29 F2 · price: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1 · derivative.exercise_date: This option was fully exercisable. F2 · derivative.exercise_date: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $100.97 | $0.00 |
DisclosureSEC source: 0001415889-19-001381 · form4-11222019_071130.xml · derivative · entry 4 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2027-10-30 F2 · price: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1 · derivative.exercise_date: This option was fully exercisable. F2 · derivative.exercise_date: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 3,125 | $0.00 Strike: $135.41 | $0.00 |
DisclosureSEC source: 0001415889-19-001381 · form4-11222019_071130.xml · derivative · entry 3 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,125 shares Expires 2027-07-31 F2 · price: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1 · derivative.exercise_date: This option was fully exercisable. F2 · derivative.exercise_date: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 3,125 | $0.00 Strike: $124.06 | $0.00 |
DisclosureSEC source: 0001415889-19-001381 · form4-11222019_071130.xml · derivative · entry 2 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,125 shares Expires 2027-05-01 F2 · price: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1 · derivative.exercise_date: This option was fully exercisable. F2 · derivative.exercise_date: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 6,563 | $0.00 Strike: $113.18 | $0.00 |
DisclosureSEC source: 0001415889-19-001381 · form4-11222019_071130.xml · derivative · entry 1 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,563 shares Expires 2027-01-30 F2 · price: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1 · derivative.exercise_date: This option was fully exercisable. F2 · derivative.exercise_date: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantRestricted Stock Units · Derivative | 2,908 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 32 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,908 Underlying: Common Stock, $0.10 par value · 2,908 shares Expires 2020-05-01 F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F6 · derivative.exercise_price: The restricted stock unit vests in three equal annual installments beginning on May 1, 2018. F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F6 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on May 1, 2018. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantOption (right to buy) · Derivative | 19,621 | $0.00 Strike: $38.41 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 31 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,621 Underlying: Common Stock, $0.10 par value · 19,621 shares Expires 2028-10-29 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantOption (right to buy) · Derivative | 19,619 | $0.00 Strike: $47.81 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 30 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,619 Underlying: Common Stock, $0.10 par value · 19,619 shares Expires 2028-07-30 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantOption (right to buy) · Derivative | 19,619 | $0.00 Strike: $44.70 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 29 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,619 Underlying: Common Stock, $0.10 par value · 19,619 shares Expires 2028-05-08 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantOption (right to buy) · Derivative | 9,299 | $0.00 Strike: $55.52 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 28 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,299 Underlying: Common Stock, $0.10 par value · 9,299 shares Expires 2028-01-29 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantOption (right to buy) · Derivative | 9,300 | $0.00 Strike: $54.29 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 27 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,300 Underlying: Common Stock, $0.10 par value · 9,300 shares Expires 2027-10-30 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantOption (right to buy) · Derivative | 5,843 | $0.00 Strike: $72.42 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 26 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,843 Underlying: Common Stock, $0.10 par value · 5,843 shares Expires 2027-07-31 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantOption (right to buy) · Derivative | 5,843 | $0.00 Strike: $66.35 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 25 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,843 Underlying: Common Stock, $0.10 par value · 5,843 shares Expires 2027-05-01 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantOption (right to buy) · Derivative | 12,272 | $0.00 Strike: $60.53 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 24 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,272 Underlying: Common Stock, $0.10 par value · 12,272 shares Expires 2027-01-30 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantOption (right to buy) · Derivative | 12,205 | $0.00 Strike: $54.94 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 23 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,205 Underlying: Common Stock, $0.10 par value · 12,205 shares Expires 2026-10-31 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantOption (right to buy) · Derivative | 5,843 | $0.00 Strike: $61.34 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 22 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,843 Underlying: Common Stock, $0.10 par value · 5,843 shares Expires 2026-08-01 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantOption (right to buy) · Derivative | 5,812 | $0.00 Strike: $56.44 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 21 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,812 Underlying: Common Stock, $0.10 par value · 5,812 shares Expires 2026-05-02 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantOption (right to buy) · Derivative | 9,299 | $0.00 Strike: $54.20 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 20 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,299 Underlying: Common Stock, $0.10 par value · 9,299 shares Expires 2026-02-01 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantOption (right to buy) · Derivative | 9,350 | $0.00 Strike: $61.01 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 19 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,350 Underlying: Common Stock, $0.10 par value · 9,350 shares Expires 2025-11-09 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantOption (right to buy) · Derivative | 9,350 | $0.00 Strike: $70.89 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 18 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,350 Underlying: Common Stock, $0.10 par value · 9,350 shares Expires 2025-07-27 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantOption (right to buy) · Derivative | 9,350 | $0.00 Strike: $58.78 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 17 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,350 Underlying: Common Stock, $0.10 par value · 9,350 shares Expires 2025-05-04 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantOption (right to buy) · Derivative | 7,012 | $0.00 Strike: $63.41 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 16 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,012 Underlying: Common Stock, $0.10 par value · 7,012 shares Expires 2025-02-02 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 27, 2019 22:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantOption (right to buy) · Derivative | 9,350 | $0.00 Strike: $62.67 | $0.00 |
DisclosureSEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 15 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,350 Underlying: Common Stock, $0.10 par value · 9,350 shares Expires 2024-12-19 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.